# Study of OT202 in Treating Moderate to Severe Dry Eye

> **NCT06435182** · PHASE2 · COMPLETED · sponsor: **Ocumension Therapeutics (Shanghai) Co., Ltd** · enrollment: 213 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** OT202 conc 0.5%
- **DRUG:** OT202 conc 0.1%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06435182
- **Lead sponsor:** Ocumension Therapeutics (Shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-10
- **Primary completion:** 2024-01-26
- **Final completion:** 2024-01-26
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435182, "Study of OT202 in Treating Moderate to Severe Dry Eye". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06435182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*